FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive Patients Noninferior to Continued Oral DTG/ABC/3TC at Wk 96

March 8-11, 2020; Boston, Massachusetts
Switch to monthly injections of long-acting cabotegravir + rilpivirine after 20-week induction with oral 3-drug ART in treatment-naive patients noninferior to continued oral 3-drug ART for the maintenance of virologic suppression at Week 96 and demonstrates higher patient-reported satisfaction.
Format: Microsoft PowerPoint (.ppt)
File Size: 253 KB
Released: March 11, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

Large, retrospective analysis supports the effectiveness and safety of dolutegravir-based regimens among children and adolescents, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

IAS 2021 report from Clinical Care Options (CCO): CUSTOMIZE study shows that HCPs think monthly injectable CAB + RTV LA is feasible and acceptable despite COVID-19 disruptions

Released: July 22, 2021

Post-hoc analysis of TANGO assessed changes in quantitative and qualitative viral load through Week 96 and inflammatory biomarkers from baseline to Week 96, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue